Who are Ag-D-CIK's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MB-102 OMID, TAK-667, KI1106 4g, QD, Open single period A140, SCTB14, HP-802-247.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ag-d-cik.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ag-D-CIK — Competitive Intelligence Brief

Ag-D-CIK (Ag-D-CIK) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47 antibody. Area: Oncology.

phase 2 CD47 antibody CD47 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Ag-D-CIK (Ag-D-CIK) — Shenzhen Hornetcorn Bio-technology Company, LTD. Ag-D-CIK is a monoclonal antibody that targets CD47.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ag-D-CIK TARGET	Ag-D-CIK	Shenzhen Hornetcorn Bio-technology Company, LTD	phase 2	CD47 antibody	CD47
MB-102 OMID	MB-102 OMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
TAK-667	TAK-667	Takeda	phase 3	CD47 antibody	CD47
KI1106 4g, QD	KI1106 4g, QD	Kuhnil Pharmaceutical Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
Open single period A140	Open single period A140	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
SCTB14	SCTB14	Sinocelltech Ltd.	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis
HP-802-247	HP-802-247	Healthpoint	phase 3	CD47 antibody	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47 antibody class)

Akeso · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Healthpoint · 1 drug in this class
Shenzhen Hornetcorn Bio-technology Company, LTD · 1 drug in this class
Takara Bio Inc. · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ag-D-CIK — Competitive Intelligence Brief. https://druglandscape.com/ci/ag-d-cik. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab